Michael Atkins
Michael Atkins
Georgetown-Lombardi Comprehensive Cancer Ctr
Verified email at
Cited by
Cited by
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
Final version of 2009 AJCC melanoma staging and classification
CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ...
Journal of clinical oncology 27 (36), 6199, 2009
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of clinical oncology 36 (17), 1714-1768, 2018
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch, AC Buzaid, SJ Soong, MB Atkins, N Cascinelli, DG Coit, ...
Journal of Clinical Oncology 19 (16), 3635-3648, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
CM Balch, SJ Soong, JE Gershenwald, JF Thompson, DS Reintgen, ...
Journal of clinical oncology 19 (16), 3622-3634, 2001
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020, 2014
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
MB Atkins, MT Lotze, JP Dutcher, RI Fisher, G Weiss, K Margolin, ...
Journal of clinical oncology 17 (7), 2105-2105, 1999
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
GT Gibney, LM Weiner, MB Atkins
The Lancet Oncology 17 (12), e542-e551, 2016
Combined nivolumab and ipilimumab in melanoma metastatic to the brain
HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ...
New England Journal of Medicine 379 (8), 722-730, 2018
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ...
Journal of clinical oncology 22 (5), 909-918, 2004
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
H Tilg, E Trehu, MB Atkins, CA Dinarello, JW Mier
Management of cutaneous melanoma
H Tsao, MB Atkins, AJ Sober
New England Journal of Medicine 351 (10), 998-1012, 2004
Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production
JP Leonard, ML Sherman, GL Fisher, LJ Buchanan, G Larsen, MB Atkins, ...
Blood, The Journal of the American Society of Hematology 90 (7), 2541-2548, 1997
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott, MM Regan, JI Clark, LE Flaherty, GR Weiss, TF Logan, ...
Journal of clinical oncology 23 (1), 133-141, 2005
The system can't perform the operation now. Try again later.
Articles 1–20